Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.

NCT Number	NCT07021937
Lead Sponsor	University of Colorado, Denver Collaborators: University of Minnesota, The Metis Foundation
Conditions	Obesity/Therapy
Enrollment	120 participants
Start Date	2026-06-15
Primary Completion	2031-04-30 (estimated)
Study Completion	2031-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-02